Innovate UK grants $2.9m to cancer enzyme inhibitor hunt
The UK government is granting £1.9m ($2.9m) to pharma company Mission Therapeutics to create small-molecule cancer inhibitors.
Archives for September 21, 2015
Novo Nordisk building its first manufacturing facility in Middle-East
Novo Nordisk injecting €70m in Iran for insulin pen production plant
Novo Nordisk will build a manufacturing plant for its FlexPen prefilled insulin device in Iran to cater for the local market.
Covance mulls sacking 130 UK staff at ex Sanofi site; Opens 2nd cGMP pharmacy in US
Covance has warned 130 UK employees they could lose their jobs next month when a 5-year contract with Sanofi comes to an end.
CRISPR
UK asks to use CRISPR on human embryos
UK scientists have applied to the country’s fertility regulator for permission to use CRISPR and other genome editing techniques on human embryos.
Potential $1.25bn deal adds CEPT inhibitor to Amgen's cardiovascular offerings
Amgen could pay up to $1.25bn Dezima Pharma if its promising lead candidate - the cholesterol buster TA-8995 - is approved.
Greatbatch: $1.7bn acq 'transfromative' in the medical device space
Standard & Poor has assigned a ‘stable’ rating to Greatbatch after the contract manufacturer secured $1.5bn to buy fellow medical devicemaker Lake Region Medical.
German CRO joins tenants on Bayer campus
Preclinical CRO NMI TT Pharmaservices is establishing a branch at Bayer’s campus in Germany.
Glide and Cilian team to develop solid dose flu vaccine
Cilian has teamed up with Glide Technologies to develop a solid dose influenza vaccine to be delivered via a needle-free injector.
Venn offers $7.2m for Kinesis to boost toxicology testing offering
Venn Life Sciences has bid €6.5m ($7.2m) for preclinical CRO Kinesis Pharma BV in a move prompted by increased Big Pharma focus of efficient early phase drug discovery.
Lack of regulatory clarity dominates US biosimilar debate post Zarxio
Sandoz has reiterated its call for US FDA guidance on biosimilar interchangeability arguing that the lack of clarity makes it hard to gauge what impact switching rules will have on pricing.